Germany's Activaero and Forest Laboratories to co-market new Colistin nebuliser for cystic fibrosis
This article was originally published in Scrip
Germany's Activaero has signed an agreement with Forest Healthcare to co-market Activaero's Akita Jet inhaler with colistin for high-dose therapy of cystic fibrosis in Germany. The partners said they have been able to demonstrate the advantages of Colistin CF (the new product's trade name) over similar inhalers and plan to introduce it to centres for the treatment of cystic fibrosis.
Akita inhalation systems are based on Activaero's Favorite (Flow And VOlume Regulated Inhalation TEchnology) technology, which enables the delivery of up to 80% of a drug into the lungs, to control patients' breathing electronically, and to adjust and improve their lung functions. Akita's inhalation systems ensure that patient receive the same dose of the medicine every time when they use the nebuliser, which is important for the long-term treatment of chronic lung diseases and for clinical trials of new drugs.
Forest Healthcare, Forest Laboratories' wholly owned subsidiary, acquired the rights to Colistin from Gruenenthal to expand its cystic fibrosis business in Europe. It said that Akita Jet inhalers could save several thousands Euros per patient in treatment costs.
Activaero is based in Gemunden, Germany, and has divisions in Munich and Dublin, Ohio. It develops, manufactures and sells inhalers for the treatment of respiratory diseases.